Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / EDRN-WHI Pre-Clinical Colon Ca Specimens

EDRN-WHI Pre-Clinical Colon Ca Specimens

126

Specifically, it is proposed to assess plasma proteins from postmenopausal women diagnosed with colon cancer within a span of 18 months after year-3 OS blood draw and from appropriate matched controls enrolled in the WHI OS study. The range of case-control differences sought in plasma include: 1 Detection and identification of proteins that may be derived from tumor cells through the classical secreted protein pathway and through non-classical pathways (eg protein cleavage and release) or through cell turnover. 2 Detection and identification of protein changes associated with the host response that occur during tumor development and that may be related to inflammation, angiogenesis, infiltration of tumor with host cells and other processes. 3 Identification of tumor derived proteins that induce a humoral immune response in the form of autoantibodies that are detectable at the preclinical stage.

Specific Aims are identified by each assay laboratory.
The primary analysis for this study is to identify proteins/peptides that have potential as colon cancer early detection or risk prediction markers for subsequent validation. The secondary aim is to see if some proteins/peptides are complementary in their early detection abilities so their combinations will improve their sensitivity and specificity. Since thousands of protein/peptides will be identified and/or quantified, one important issue is to quantify and control the False Discovery Rate (# of false positive finding / # of selected markers as differentially expressed) and maintain reasonable power to detect truly differentially expressed markers. Another important feature of the data analysis is that the derived data from mass spectrometry critically depends on the algorithms of identifying the peptides, assigning protein identities and intensities. Coordinating center biostatisticians need work closely with proteomics bioinformaticians and computational biologists with expected iterations between data processing and data analyses.

There are currently no biomarkers annotated for this protocol.


Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.